Summary:
- Tenax Therapeutics has been selected to present Phase 3 clinical trial results for their investigational drug, levosimendan, during a late-breaking scientific session at the ESC Congress 2026.
- The presentation will focus on the efficacy and safety data of the drug in treating patients with pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), marking a significant milestone in cardiovascular clinical research.